Nanotechnology Now - Press Release: BioAlliance Pharma SA : announces participation in the MidCap Event on September 29 and 30, 2008

Home > Press > BioAlliance Pharma SA : announces participation in the MidCap Event on September 29 and 30, 2008

Abstract:
BioAlliance Pharma SA (Euronext Paris: FR0010095596-BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today announced that it will participate in the MidCap Event, a forum dedicated to meetings between institutional investors and listed companies from the Euronext Zone, on Monday 29 and Tuesday 30 of September in Paris. The MidCap Event will take place at the Palais Brongniart, 19 rue Notre-Dame des Victoires 75002 PARIS.

BioAlliance Pharma SA : announces participation in the MidCap Event on September 29 and 30, 2008

PARIS, France | Posted on September 16th, 2008

During these two days, Dominique Costantini, President and Chief Executive Officer, Pierre Morgon, Chief Operating Officer in charge of commercial operations, and Nicolas Fellmann, Chief Financial Officer, will meet with institutional investors to present BioAlliance Pharma's development strategy, as well as the significant advances that were achieved during the first semester.

####

About BioAlliance Pharma SA
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address drug resistance issues. BioAlliance Pharma has launched its first portfolio product (Loramyc®) in France and, more recently, in the UK, Germany and Denmark, and has already received European Marketing Authorizations in Belgium and Luxemburg. The product has also completed a pivotal Phase III clinical trial in the United States in oropharyngeal candidiasis. The company is also performing a Phase III trial in labial herpes with acyclovir Lauriad® (which is based on the same Lauriad® muco-adhesive technology as Loramyc®, enabling targeted release at the disease site). BioAlliance Pharma also has a second technology (the Transdrug® nanoparticle technology, designed specifically for intracellular targeting) and, furthermore, is developing a new therapeutic entities program in oncology and infectious disease. BioAlliance Pharma has established several strategic alliances for commercializing Loramyc®, with agreements in 2007 for Europe (with the SpeBio joint venture) and the United States (with Par Pharmaceutical) and in 2008 for Asia (Korea, Malaysia, Singapore and Taiwan with Handok Pharmaceuticals and then China with Novamed). In May and August 2008, the company expanded its product portfolio by acquiring the Europe commercial rights to, respectively, ondansetron Oral Spray (OS) from NovaDel Pharma Inc. (Amex: NVD) and ondansetron RapidFilmTM from APR/Labtec.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 11 2008 under the number R. 08-021, which is available on the AMF website (www.amf-france.org) or on BioAlliance Pharma S.A.'s website (www.bioalliancepharma.com).

For more information, please click here

Contacts:
BioAlliance Pharma SA

Dominique Costantini
President and CEO
Tel.: +33 1 45 58 76 01

Nicolas Fellmann
CFO
Tel.: +33 1 45 58 71 00

ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59

This information is provided by HUGIN